Guanfacine for Daytime Hyperarousal in Adult PTSD

Limitations of Current Evidence

The American Academy of Sleep Medicine notes that clonidine received only a Level C recommendation for PTSD-associated nightmares, based on low-grade evidence from two small case series in Cambodian refugees, showing nightmare reduction at 0.2-0.6 mg divided doses 1, 2
The American Academy of Sleep Medicine states that no randomized placebo-controlled trials of clonidine for the treatment of nightmares or other aspects of PTSD have been reported, despite 20+ years of clinical use 1, 2
The mechanism of clonidine, suppressing sympathetic nervous system outflow throughout the brain, would theoretically help with arousal symptoms, but the clinical data only demonstrates efficacy for sleep-related manifestations 1, 2

Both clonidine and guanfacine list somnolence, fatigue, and sedation as their most common adverse effects, making them unsuitable for daytime hyperarousal management 3
The American Academy of Sleep Medicine recommends administration of alpha-2 agonists in the evening due to the relatively frequent occurrence of somnolence/fatigue as an adverse effect 4, 3
The pharmacokinetics of guanfacine extended-release provides "around-the-clock" effects, meaning it cannot selectively target daytime vs. nighttime symptoms 4, 3

Patients taking guanfacine must be warned about orthostatic hypotension, bradycardia, and daytime sedation that could impair driving and work function 1, 3, 2
The dose-response relationships for guanfacine differ significantly between pediatric and adult populations, with pediatric effective doses being 0.03 mg/kg vs. adult ADHD doses of 0.1 mg/kg 4